PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR-Reference-Cited by-同舟云学术

PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

Published:2021-05 Issue:8 Volume:35 Page:109181
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Ghosh Soma,Nataraj Nishanth Belugali^ORCID,Noronha Ashish,Patkar Sushant,Sekar Arunachalam,Mukherjee Saptaparna,Winograd-Katz Sabina,Kramarski Lior,Verma Aakanksha,Lindzen Moshit,Garcia Diana Drago,Green Joseph^ORCID,Eisenberg Galit,Gil-Henn Hava,Basu Arkaprabha^ORCID,Lender Yan,Weiss Shimon^ORCID,Oren Moshe,Lotem Michal,Geiger Benjamin,Ruppin Eytan,Yarden Yosef

Funder

Israel Cancer Research Fund

European Research Council

Israel Science Foundation

Doctor Miriam and Sheldon G Adelson Medical Research Foundation

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference61 articles.

1. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors;Akbay;Cancer Discov.,2013

2. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics;Akinleye;J. Hematol. Oncol.,2019